心外膜脂肪衰减动态变化提示LDL-C降低后的残余斑块风险
对313例无症状未用他汀者的CAUGHT-CAD试验事后分析显示,心外膜脂肪组织衰减变化ΔEAT attenuation与冠脉非钙化斑块进展及不良重构独立相关,而EAT体积变化无此关联。
要点
- 报告冠脉CTA随访时,除管腔与斑块外,应关注EAT衰减变化而非仅报告EAT体积。
- ΔEAT attenuation升高与NCP体积、纤维斑块体积及NCP PAV进展独立相关,提示残余炎症风险。
- 基线EAT体积较大者,ΔEAT attenuation可为LDL-C模型提供增量信息。
核心结论
- EAT衰减的动态变化与冠脉斑块重构相关,且独立于LDL-C降低。
- 心外膜脂肪炎症可能在残余斑块进展中发挥潜在机制作用。
研究设计与样本
- 研究类型为随机对照试验CAUGHT-CAD的事后分析。
- 共纳入313例无症状、未接受他汀治疗的参与者,平均年龄58.8±6.8岁,女性占44%。
- 采用配对基线与随访冠脉CTA进行斑块与EAT定量。
- 统计分析使用协方差模型,校正基线斑块负荷、治疗分配及心血管代谢危险因素变化。
- 通过嵌套模型比较与似然比检验评估ΔEAT attenuation相对LDL-C参考模型的增量判别能力。
关键影像表现/征象
- ΔEAT attenuation升高与NCP体积、纤维斑块体积及NCP PAV进展相关。
- ΔEAT attenuation升高与不良斑块重构独立相关。
- 探索性分析显示ΔEAT attenuation与ΔPCAT attenuation升高相关。
- EAT体积变化与NCP进展及不良重构无独立相关。
诊断标准与关键数值
- ΔEAT attenuation每升高1个SD,NCP体积高4.21 mm3(95% CI:0.67-7.74;P=0.020)。
- ΔEAT attenuation每升高1个SD,纤维斑块体积高3.55 mm3(95% CI:0.67-6.43;P=0.016)。
- ΔEAT attenuation每升高1个SD,NCP PAV高1.08%(95% CI:0.47-1.69;P<0.001)。
- LDL-C参考模型分层:<1.4 mmol/L(<55 mg/dL)、1.4-1.8 mmol/L(55-70 mg/dL)、>1.8 mmol/L(>70 mg/dL)。
- 基线EAT体积第三分位≥67.1 cm3者,加入ΔEAT attenuation后模型拟合改善,ΔAIC为-4.8,似然比检验P=0.012。
临床应用与阅片要点
- 随访冠脉CTA报告中可增加EAT衰减变化描述,作为LDL-C降低后残余炎症风险的参考。
- 基线EAT体积较大者更可能从ΔEAT attenuation评估中获益。
- 解读ΔEAT attenuation时需注意其与PCAT attenuation升高相关,可能部分反映血管周围脂肪炎症。
- 不应仅用EAT体积变化判断残余风险,本研究中EAT体积变化无独立预测价值。
局限性
- 研究为事后分析,结果需在前瞻性设计中进一步验证。
- 探索性PCAT分析仅为关联性结果,不能证明因果关系。
- 研究对象为无症状未用他汀人群,结果不一定适用于已接受他汀治疗或有症状患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Coronary plaque progression persists in some patients despite effective low-density lipoprotein cholesterol (LDL-C) lowering. Epicardial adipose tissue (EAT) is a metabolically active visceral fat depot that may influence coronary atherosclerosis through inflammatory signaling. The authors hypothesized that longitudinal changes in EAT would influence plaque progression.
METHODS: Plaque and EAT quantification with paired baseline and follow-up coronary computed tomography angiography was attainable in 313 asymptomatic, statin-naive participants (aged 58.8 ± 6.8 years, 44% female) in the CAUGHT-CAD (Coronary Artery calcium score: Use to Guide management of Hereditary Coronary Artery Disease) trial. Associations between longitudinal changes in EAT volume and attenuation (ΔEAT) and coronary plaque outcomes were evaluated using analysis of covariance models, with adjustment for baseline plaque burden, treatment allocation, and changes in cardiometabolic risk factors. Exploratory analyses evaluated the relationship between ΔEAT attenuation and Δ pericoronary adipose tissue (PCAT) attenuation. An LDL-C-based reference model of achieved LDL-C (Reference: <1.4 mmol/L [<55 mg/dL], 1.4-1.8 mmol/L [55-70 mg/dL], and >1.8 mmol/L [>70 mg/dL]) was used, and incremental discrimination with ΔEAT attenuation was assessed using nested model comparison and likelihood ratio testing.
RESULTS: Higher ΔEAT attenuation, but not EAT volume change, remained independently associated with progression of noncalcified plaque (NCP) and adverse plaque remodeling. Per 1-SD increase in ΔEAT attenuation, NCP volume was higher by 4.21 mm3 (95% CI: 0.67-7.74; P = 0.020), fibrous plaque volume by 3.55 mm3 (95% CI: 0.67-6.43; P = 0.016), and NCP percent atheroma volume by 1.08% (95% CI: 0.47-1.69; P < 0.001). In participants with high baseline EAT volume (tertile 3 ≥67.1 cm3), the addition of ΔEAT attenuation to LDL-C-based analysis of covariance models resulted in a statistically significant improvement in model fit (Δ Akaike information criterion -4.8; likelihood ratio test P = 0.012). In exploratory analyses, ΔEAT attenuation was also associated with increasing PCAT attenuation (β = 2.44 HU per SD; P < 0.001), suggesting that changes in PCAT may partly explain the observed association with plaque progression.
CONCLUSIONS: The association of serial changes in EAT attenuation with coronary plaque remodeling, independent of LDL-C lowering, supports a potential mechanistic role for EAT inflammation in residual plaque progression.
引用
- Khanna, Xu, Soh, et al. Serial Changes in Epicardial Adipose Tissue Attenuation Identify Residual Atherosclerotic Risk Independent of LDL Lowering: A Post Hoc Analysis of the CAUGHT-CAD Trial. JACC Cardiovasc Imaging. 2026. PMID: 42417694. doi:10.1016/j.jcmg.2026.05.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。